Schedule III Cannabis Order Faces New Court Stay Request
Legal team reviewing documents tied to the Schedule III cannabis court challenge.
Federal cannabis reform is still facing legal attack. Cannabis Business Times reports that the National Drug and Alcohol Screening Association and MMJ International Holdings asked the U.S. Court of Appeals for the District of Columbia Circuit to stay the federal order that moved state licensed medical cannabis to Schedule III. The challengers argue the order bypassed required procedures and could cause business harm to drug testing groups and pharmaceutical cannabinoid developers. For operators, investors, lenders, attorneys, compliance teams, and medical cannabis companies, this is a reminder that Schedule III is not just a policy win. It is now a litigation risk event.
Quick facts
• The National Drug and Alcohol Screening Association and MMJ International Holdings filed a motion on June 9
• The motion asks the D.C. Circuit to pause the Schedule III order while the underlying lawsuit is reviewed
• The challenged order moved FDA approved cannabis products and state licensed medical cannabis to Schedule III
• The challengers argue the order unlawfully bypassed notice and comment rulemaking
• NDASA says members may face drug testing policy costs and medical review officer revenue pressure
• MMJ says the order could harm its cannabinoid drug development position and market opportunities
• Cannabis Business Times reports the DOJ has until July 2 to respond
• The universal operator lesson is simple: federal reform can create opportunity and uncertainty at the same time
If Schedule III uncertainty is affecting your growth plan, complete our quick Cannashield intake form so you can map licensing, compliance, tax, financing, and insurance exposure before court action changes the timeline.
Why the stay request matters
This motion matters because it attacks the foundation of the immediate Schedule III order. The challengers are not only arguing about policy. They are arguing about process. They claim the acting attorney general exceeded authority by using a treaty based pathway under the Controlled Substances Act instead of going through a fuller administrative process.
That is important because operators have already begun making business decisions around the new federal framework. Medical cannabis companies are reviewing DEA registration pathways. Public companies are restructuring around medical operations. Lenders and investors are watching tax treatment, market access, and compliance posture. If a court stay pauses the order, those decisions could become more complicated fast.
Why operators should not treat reform as final yet
The cannabis industry has spent years waiting for federal movement. Schedule III created a major shift, especially for state licensed medical cannabis operators. But litigation means the industry needs to be careful about assuming everything is settled.
A stay would not necessarily decide the entire case. It could simply pause the order while the court reviews the legal challenge. But even a pause could create uncertainty around DEA registration, tax planning, investor communication, lender underwriting, and medical market strategy.
This is the universal operator lesson. A federal win is not fully bankable until the legal pathway survives challenge.
If uncertainty around DEA registration, 280E planning, or medical license strategy is affecting how you plan, complete our Cannashield questionnaire to pressure test your exposure before litigation shifts the operating assumptions.
Why drug testing groups and pharmaceutical developers are involved
The parties challenging the order show how cannabis reform affects more than plant touching operators. NDASA represents drug testing and workplace screening interests. It argues that Schedule III could force employers and medical review practices to adjust policies and absorb unrecoverable costs. MMJ International Holdings says it invested years and millions of dollars developing cannabinoid based drugs through the traditional FDA and DEA pathway, and that the order could undercut its market position.
That matters because cannabis reform creates winners and losers across adjacent industries. Medical operators may benefit from Schedule III. Drug testing groups may face policy complexity. Pharmaceutical cannabinoid developers may argue that state licensed products are gaining a faster lane than products moving through traditional approval channels.
Legal team reviewing documents tied to the Schedule III cannabis court challenge.
What lenders and investors should watch
For lenders and investors, the key question is not just whether Schedule III survives. The question is how much uncertainty exists while the case moves forward. Capital markets do not like unstable rules. If tax relief, DEA registration, and medical operator legitimacy become tied to court timing, underwriting needs to reflect that risk.
Investors should watch the DOJ response, any order on the stay request, and whether the D.C. Circuit signals concern about the government’s use of Section 811(d)(1). Lenders should review covenants, borrower projections, tax assumptions, and whether the borrower is depending too heavily on a Schedule III benefit that could be delayed.
If you need to organize licensing, financing, tax, and insurance records before the DOJ response or court decision, use the Cannashield intake form to identify weak points and build a cleaner risk file.
You might also like
Conclusion
The request to stay the Schedule III cannabis order is a warning that federal reform is still contested. The order may have opened a new path for state licensed medical cannabis, but the path now runs through the courts.
For operators, investors, lenders, compliance teams, and medical cannabis companies, the message is simple. Keep planning, but do not plan blindly. Schedule III may change the industry, but litigation could still affect timing, registration strategy, tax assumptions, and market confidence.
Educational note: This article is for education only and is not legal, regulatory, tax, financial, investment, employment, pharmaceutical, or insurance advice.
What To Do This Week
• Track the DOJ response deadline and any court order on the stay request
• Review whether your business assumptions depend on Schedule III remaining in effect
• Recheck DEA registration readiness and medical license documentation
• Model tax, lending, and investor scenarios if the order is paused
• Review communications with lenders, investors, landlords, and board members for overconfidence
• Build a short internal memo on litigation exposure, timing risk, and backup planning
FAQ
What happened?
The National Drug and Alcohol Screening Association and MMJ International Holdings asked the D.C. Circuit to stay the Schedule III cannabis order.
What does a stay mean?
A stay would pause the order while the court reviews the underlying legal challenge.
What order is being challenged?
The order moved FDA approved cannabis products and state licensed medical cannabis to Schedule III.
Why are the challengers objecting?
They argue the order bypassed required procedures and could cause business harm to drug testing groups and pharmaceutical cannabinoid developers.
When must the DOJ respond?
Cannabis Business Times reports that the DOJ has until July 2 to respond.
What is the biggest operator takeaway?
Schedule III may create opportunity, but operators still need backup plans because litigation could create fresh uncertainty.
SOURCES
Cannabis Business Times, Anti Rescheduling Parties Ask Court to Stay Schedule III Cannabis Order
https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15827471/antirescheduling-parties-ask-court-to-stay-schedule-iii-cannabis-order
U.S. Department of Justice, Final Order Rescheduling FDA Approved Products and State Licensed Medical Cannabis
https://www.justice.gov/opa/media/1437441/dl
Reuters, Cannabis rescheduling arrives, with limits
https://www.reuters.com/legal/litigation/cannabis-rescheduling-arrives-with-limits-what-dojs-final-order-does-doesnt-do--pracin-2026-05-12/
SQDC reported $809.5 million in sales for fiscal 2025 2026, with $132.4 million in net income and a $331.3 million contribution to the Quebec government. The bigger lesson is that government run cannabis retail can keep growing through store expansion, vape access, pricing discipline, and legal market capture.